Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder
about
Novel pharmacologic treatment in acute binge eating disorder - role of lisdexamfetamineCognitive remission: a novel objective for the treatment of major depression?Neurobiology of hedonic tone: the relationship between treatment-resistant depression, attention-deficit hyperactivity disorder, and substance abuseStimulants for depression: On the up and up?Cognitive dysfunction in major depressive disorder: effects on psychosocial functioning and implications for treatment.Effect of antidepressant treatment on cognitive impairments associated with depression: a randomised longitudinal study.Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological TreatmentsThe use of lisdexamfetamine dimesylate for the treatment of ADHD and other psychiatric disorders.The prevalence, measurement, and treatment of the cognitive dimension/domain in major depressive disorder.Treating to target in major depressive disorder: response to remission to functional recovery.Drugs, games, and devices for enhancing cognition: implications for work and society.Managing comorbid obesity and depression through clinical pharmacotherapies.Adult ADHD and comorbid disorders: clinical implications of a dimensional approach.A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy.Association of psychological, cognitive, and functional variables with self-reported executive functioning in a sample of nondemented community-dwelling older adults.Addictive potential of novel treatments for refractory depression and anxiety.
P2860
Q26752974-F6E3E27D-44A4-4BE0-A46D-B2DA696A256DQ26775386-25223D56-1C5F-4AC2-9A66-D326AFC992ADQ28076105-CA910B24-AF2B-47DB-BF2C-8E00F15FB0D5Q34515266-03457D1E-92A8-46AD-9BD9-A948841995AFQ35006371-CD4B7344-0715-4538-AD93-396879733859Q36880463-15C3F594-C80C-4295-B293-977C789A15ECQ37197216-D057E28D-C683-40F4-BC16-8CBF381F3173Q38221823-8E12D619-320A-4BA1-9F39-29C786091B7CQ38569937-49BF0664-5A21-4EEB-A7AA-BF1383CEC473Q38673546-8A4A0F06-E306-4E95-BC78-A33584C559E7Q38797653-91E53AAE-BB47-4012-90AB-1D20FE8F0970Q38859885-D4482672-C126-43EC-AB09-EE66389AF025Q41495299-47FD2C1E-75D0-43AE-A8D6-1C5433AF6A27Q42361284-F9869400-FE01-47AD-9C0B-31E44B62F00AQ48052666-79F35990-9BB8-42B9-B4ED-24D9AA3FE8B1Q55334438-6A951DE7-EEEC-47F9-AE3C-F802C241E3A5
P2860
Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lisdexamfetamine dimesylate au ...... n of major depressive disorder
@en
Lisdexamfetamine dimesylate au ...... of major depressive disorder.
@nl
type
label
Lisdexamfetamine dimesylate au ...... n of major depressive disorder
@en
Lisdexamfetamine dimesylate au ...... of major depressive disorder.
@nl
prefLabel
Lisdexamfetamine dimesylate au ...... n of major depressive disorder
@en
Lisdexamfetamine dimesylate au ...... of major depressive disorder.
@nl
P2093
P2860
P356
P1476
Lisdexamfetamine dimesylate au ...... n of major depressive disorder
@en
P2093
Angelo Sambunaris
Colleen S Anderson
Madhukar H Trivedi
Manisha Madhoo
Richard S E Keefe
Robert Lasser
Robert M Roth
P2860
P2888
P304
P356
10.1038/NPP.2013.334
P407
P577
2013-12-06T00:00:00Z